Clostridium difficile infection in hospitals: Risk factors and responses

CMAJ. Canadian Medical Association Journal

Volumn 171, Issue 1, 2004, Pages 45-46

  Louie, Thomas J ^a,b   Meddings, Jon ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LANSOPRAZOLE; PROTON PUMP INHIBITOR;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; DIARRHEA; DISEASE ASSOCIATION; GOOD LABORATORY PRACTICE; HOSPITAL INFECTION; HOST RESISTANCE; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MEDICAL PRACTICE; NOTE; RISK ASSESSMENT; RISK FACTOR;

EID: 3142746628     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1040966     Document Type: Note

References (19)

1. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171(1):33-8.
2. Kaunitz JD, Sachs G. Identification of a vanadate-sensitive potassium-dependent proton pump from rabbit colon. J Biol Chem 1986;261(30):14005-10.
3. Sangan P, Rajendran PM, Mann AS, Kashgarian M, Binder HJ. Regulation of colonic H+-K+-ATPase in large intestine and kidney by dietary Na depletion and dietary K depletion. Am J Physiol 1997;272(2 pt 1):C685-96.
4. Takahashi Y, Sakai H, Kuragari M, Suzuki T, Tauchi K, Minamura T, et al. Expression of ATP1AL1, a non-gastric proton pump, in human colorectum. Jpn J Physiol 2002;52(3):317-21.
5. Nakamura M, Oda M, Akiba Y, Inoue J, Ito J, Tsuchiya M, et al. Autoradiographic demonstration of lansoprazole uptake sites in rat antrum and colon. J Clin Gastroenterol 1995;20(Suppl 2):S8-13.
6. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54(3):243-5.
7. Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M. The Canadian Hospital Epidemiology Committee and Canadian Nosocomial Infection Surveillance Program. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002;23:137-40.
8. Hirschhorn LR, Trnka Y, Onderdonk A, Lee ML, Platt R. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994;169:127-33.
9. Maxwell S, Hudson F. An investigation into the carriage of Clostridium difficile on the hands of health care workers. P854. Clin Microbiol Infect 2004;10(Suppl 3):220.
10. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998;41(Suppl C):21-7.
11. Impallomeni M, Galletly NP, Wort SJ, Starr JM, Rogers TR. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. BMJ 1995;311(7016):1345-6.
12. Gaynes R, Rimland D, Killum E, Lowery HK, Johnson II TM, Killgore G, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640-5.
13. Johnson S, Samore MH, Farrow KA, Killgore GE, Tenover FC, Lyras D, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999;341(22):1645-51.
14. Gorbach SL. Antibiotics and Clostridium difficile. N Engl J Med 1999;341:1690-1.
15. Tvede M, Rask-Madsen J. Bacteriobiotherapy for chronic relapsing Clostridium difficile disease in six patients. Lancet 1989;1:1156-60.
16. Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med 2003;163:972-8.
17. Kurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, Rinard E, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 2001;45:2340-7.
18. Davidson D, Peppe J, Louie T. The Tolevamer Working Group. A phase 2 study of the toxin binding polymer tolevamer in patients with Clostridium difficile-associated diarrhoea. P548. Clin Microbiol Infect 2004:10(Suppl 3):124.
19. Louie T, Byrne B, Emery J, Krulicki W, Ward L, MacCannell DR, et al. Tolevamer (GT160-246) binds Clostridium difficile cytotoxins A/B and is associated with restoration of components of the anaerobic intestinal microflora during treatment of C. difficile-associated diarrhea. P855. Clin Microbiol Infect 2004:10(Suppl 3):220.